Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
RNAZ
$1.66
-2.35%
RNAZ
· Transcode Therapeutics, Inc.
$1.66
-0.04 (-2.35%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed Aug 14, 2026
Market Cap
$28.78M
Shares
16.93M
Volume · Oct 20
20.23K
Avg daily vol (3M)
53.41K
All webcasts
Earnings call · FY2022 Q1
Transcode Therapeutics, Inc. (RNAZ) Q1 2022 Earnings Call
Diluted EPS
-$199584.00
Net income
-$3.47M
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Apr 1, 2022 · complete as-filed document
SEC periodic report
10-Q report
Filed May 16, 2022 · complete as-filed document